SI-BONE to report second quarter 2026 results on August 3

0 min read     Updated on 21 Jul 2026, 01:53 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

SI-BONE will announce Q2 2026 financial results on August 3, 2026, followed by a conference call. The webcast will be available for replay for 90 days. The company specializes in procedural solutions for compromised bone.

powered bylight_fuzz_icon
46124607

*this image is generated using AI for illustrative purposes only.

SI-BONE, Inc. will report its financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. The company develops procedural solutions for clinical challenges associated with compromised bone. Management will host a conference call to discuss the results, providing investors with an update on performance and strategic initiatives.

Conference Call Details

The conference call is scheduled to begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors can register for the call through a dedicated link. Live audio of the webcast will be accessible on the "Investors" section of the company’s website.

Access and Replay

The webcast will be archived and available for replay for at least 90 days following the event. This ensures that stakeholders unable to attend the live session can access the information at a later date.

Company Overview

SI-BONE is a global leader in developing procedural solutions for compromised bone, with a focus on biomechanical design and anatomy-specific innovation. The company’s technology platform centers on spinopelvic anatomy. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures. Its clinical evidence includes four randomized controlled trials and over 185 peer-reviewed publications.

What strategic initiatives will management highlight during the call to drive growth in the second half of 2026?

How might the financial results reflect the company’s progress in expanding its procedural solutions for compromised bone?

What market trends or competitive dynamics could impact SI-BONE’s performance in the upcoming quarters?

like20
dislike

Truist Securities maintains Buy on SI-BONE, raises target to $21

0 min read     Updated on 17 Jul 2026, 12:22 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Truist Securities analyst Richard Newitter maintained a Buy rating on SI-BONE (NASDAQ: SIBN) and raised the price target to $21 from $18.

powered bylight_fuzz_icon
45773529

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Richard Newitter has maintained a Buy rating on SI-BONE (NASDAQ: SIBN) and increased the price target to $21 from $18. The adjustment reflects a revised outlook on the company's stock performance.

Rating and Price Target Details

The analyst's recommendation underscores confidence in SI-BONE's market position. The new price target of $21 represents an increase from the prior target of $18.

Metric Value
Rating Buy
Previous Price Target $18
New Price Target $21

The stock trades under the ticker symbol SIBN on the NASDAQ.

What specific factors drove the analyst's decision to raise the price target?

How might SI-BONE's recent product developments influence its market position?

What are the potential risks that could hinder SI-BONE from reaching the new price target?

like20
dislike